Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

Phase 1 Completed 109 enrolled Astellas Pharma Global Development, Inc. Kyowa Kirin, Inc. · collab

RandomizedParallel-groupQuadruple-blind

Summary

The objective of this study is to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of ASKP1240 after a single intravenous dose at escalating dose levels in healthy subjects.

Timeline

Start: 2009-01
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASP1240	Unknown	—	Intravenous

Indications

No indication recorded.